Literature DB >> 29801920

Head and Neck Cancer and the Elderly Patient.

Brian P Cervenka1, Shyam Rao2, Arnaud F Bewley3.   

Abstract

Management of head and neck cancer in the elderly patient is particularly challenging given the high morbidity associated with treatment. Surgery, radiotherapy, and chemotherapy have all been demonstrated as effective in older patients; however, older patients are more susceptible to treatment-induced toxicity, which can limit the survival benefits of certain interventions. This susceptibility is better associated with the presence of multiple comorbidities and decreasing functional status than with age alone. Screening tools allow for risk stratification, treatment deintensification, and even treatment avoidance in patients who are deemed at high-risk of being harmed by standard therapy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Comprehensive elderly assessment; Elderly medicine; Head and neck cancer; Radiation therapy; Surgical therapy

Mesh:

Year:  2018        PMID: 29801920     DOI: 10.1016/j.otc.2018.03.004

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  6 in total

1.  [Head and neck cancer in the elderly-current aspects].

Authors:  B Höing; S Lang; M Stuschke; S Hansen
Journal:  HNO       Date:  2020-03       Impact factor: 1.284

2.  Effectiveness of Geriatric Assessment-Driven Interventions on Survival and Functional and Nutritional Status in Older Patients with Head and Neck Cancer: A Randomized Controlled Trial (EGeSOR).

Authors:  Elena Paillaud; Lydia Brugel; Chloe Bertolus; Melany Baron; Emilie Bequignon; Philippe Caillet; Thomas Schouman; Jean Lacau Saint Guily; Sophie Périé; Eric Bouvard; Marie Laurent; Didier Salvan; Laurence Chaumette; Laure de Decker; Benoit Piot; Beatrix Barry; Agathe Raynaud-Simon; Elisabeth Sauvaget; Christine Bach; Antoine Bizard; Abderrahmane Bounar; Aurelien Minard; Bechara Aziz; Eric Chevalier; Dominique Chevalier; Cedric Gaxatte; Olivier Malard; Evelyne Liuu; Sandrine Lacour; Laetitia Gregoire; Charlotte Lafont; Florence Canouï-Poitrine
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

3.  Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa.

Authors:  Chuan-Chien Yang; Ching-Feng Lien; Tzer-Zen Hwang; Chih-Chun Wang; Chien-Chung Wang; Yu-Chen Shih; Shyh-An Yeh; Meng-Che Hsieh
Journal:  Cancers (Basel)       Date:  2022-05-10       Impact factor: 6.575

Review 4.  Special considerations for elderly patients with head and neck cancer during the COVID-19 pandemic.

Authors:  Arun Sharma; Dana L Crosby
Journal:  Head Neck       Date:  2020-04-28       Impact factor: 3.147

5.  Comparison between three age-stratified cohorts reveals poor prognosis of young patients with tongue carcinoma.

Authors:  Daisuke Baba; Kazuto Matsuura; Masashi Wakabayashi; Yohei Morishita; Yukio Nishiya; Wataru Okano; Toshifumi Tomioka; Takeshi Shinozaki; Ryuichi Hayashi
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

6.  Impact of adjuvant radiation therapy after definitive surgery in senior adults >80 years old with advanced head and neck squamous cell carcinoma on overall survival.

Authors:  Joann M Butkus; Meghan Crippen; Voichita Bar-Ad; Adam Luginbuhl
Journal:  Front Oncol       Date:  2022-09-30       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.